- Home
- ICLR vs SF Comparison
ICLR vs SF Comparison
Compare ICLR & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- SF
- Stock Information
- Founded
- ICLR 1990
- SF 1890
- Country
- ICLR Ireland
- SF United States
- Employees
- ICLR N/A
- SF N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- SF Investment Bankers/Brokers/Service
- Sector
- ICLR Health Care
- SF Finance
- Exchange
- ICLR Nasdaq
- SF Nasdaq
- Market Cap
- ICLR 11.6B
- SF 9.8B
- IPO Year
- ICLR 1998
- SF N/A
- Fundamental
- Price
- ICLR $150.41
- SF $108.25
- Analyst Decision
- ICLR Buy
- SF Hold
- Analyst Count
- ICLR 12
- SF 8
- Target Price
- ICLR $187.82
- SF $109.86
- AVG Volume (30 Days)
- ICLR 1.1M
- SF 707.7K
- Earning Date
- ICLR 07-23-2025
- SF 07-23-2025
- Dividend Yield
- ICLR N/A
- SF 1.70%
- EPS Growth
- ICLR 11.53
- SF 19.51
- EPS
- ICLR 9.19
- SF 5.24
- Revenue
- ICLR $8,192,621,999.00
- SF $5,030,597,000.00
- Revenue This Year
- ICLR N/A
- SF $8.07
- Revenue Next Year
- ICLR $2.10
- SF $10.55
- P/E Ratio
- ICLR $16.55
- SF $20.64
- Revenue Growth
- ICLR N/A
- SF 14.86
- 52 Week Low
- ICLR $125.10
- SF $73.27
- 52 Week High
- ICLR $347.72
- SF $120.64
- Technical
- Relative Strength Index (RSI)
- ICLR 57.67
- SF 69.34
- Support Level
- ICLR $146.56
- SF $96.54
- Resistance Level
- ICLR $155.90
- SF $109.71
- Average True Range (ATR)
- ICLR 4.88
- SF 2.24
- MACD
- ICLR 0.23
- SF 0.41
- Stochastic Oscillator
- ICLR 57.80
- SF 82.37
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.